Spinocerebellar ataxia type 2
MONDO:0008458A subtype of type I autosomal dominant cerebellar ataxia (ADCA type I) characterized by truncal ataxia, dysarthria, slowed saccades and less commonly ophthalmoparesis and chorea.
Also known as: ATXN2 autosomal dominant cerebellar ataxia type I, OPCA2, SCA2, autosomal dominant cerebellar ataxia type I caused by mutation in ATXN2, spinocerebellar ataxia type 2, ALS13, SCA 2, Wadia swami syndrome
38 clinical trials for this condition and its sub-types, 10 tagged with Spinocerebellar ataxia type 2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Spinocerebellar ataxia type 2
-
New drug aims to tackle rare brain disease
Disease control OngoingThis early-stage trial tests a single injection of ARO-ATXN2 in 36 adults with spinocerebellar ataxia type 2, a rare genetic disorder that affects movement and coordination. The main goal is to see if the drug is safe and how the body processes it. Participants are randomly assig…
Phase 1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug could slow rare brain disease that steals balance
Disease control OngoingThis phase 3 trial tests whether the drug troriluzole can slow the progression of spinocerebellar ataxia, a rare genetic disorder that affects coordination and balance. About 300 adults with different types of SCA are randomly assigned to take either troriluzole or a placebo dail…
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug slow rare brain disease? new study uses Real-World data to find out
Disease control OngoingThis study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC